An FDA advisory committee has voted that Amgen’s confirmatory phase 3 trial for KRAS inhibitor Lumakras is not enough to support full approval, but it seems unlikely that the first-to-market ...

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...

I always wanted to make a difference, but I never expected my biggest impact to come through cancer. Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a ...

This article includes detailed information about drugs approved by the FDA for oncology indications in 2025. In March, the US Food and Drug Administration (FDA) approved several treatments for a ...